{
    "clinical_study": {
        "@rank": "104171", 
        "arm_group": {
            "arm_group_label": "Methotrexate", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the human factors/usability of Rheumatoid Arthritis (RA) patients with the\n      Metoject\u00ae prefilled pen (including a label comprehension assessment and a device robustness\n      evaluation)."
        }, 
        "brief_title": "Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis (RA)", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Is a suitable candidate for treatment with Methotrexate for Rheumatoid Arthritis\n\n          -  Male or female patient who is 16 years of age or older\n\n        Exclusion Criteria:\n\n          -  Is a female patient who is pregnant, trying to become pregnant, or breast feeding, or\n             of childbearing potential, sexually active and not practicing a highly reliable\n             method of birth control during the study and at least 6 months thereafter\n\n          -  Has any history of hypersensitivity to the investigational medicinal product\n\n          -  Has a history of or current inflammatory arthritis or rheumatic autoimmune disease\n             other than Rheumatoid Arthritis (RA)\n\n          -  Is unable to comprehend written labeling and training materials"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "105", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01871961", 
            "org_study_id": "MC-MTX.15/HF"
        }, 
        "intervention": {
            "arm_group_label": "Methotrexate", 
            "intervention_name": "Methotrexate (Metoject\u00ae prefilled pen)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "South Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33143"
                }, 
                "name": "Rheumatology Arthitis & Rheumatic Care center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of Rheumatoid Arthritis Patient Performance Using the Metoject\u00ae Prefilled Pen (Methotrexate 50 mg/mL, Prefilled Pen) for Subcutaneous Injection and Subsequent Pharmacokinetic Assessment of Drug Delivery", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Questionnaires to assess the comprehension of the label (instruction for use of the prefilled pen) and device robustness evaluation after usage of the prefilled pen", 
            "measure": "To evaluate the human factors/usability of Rheumatoid Arthritis (RA) patients with the Metoject\u00ae prefilled pen (including a label comprehension assessment and a device robustness evaluation).", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01871961"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "medac GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "medac GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}